Navigation Links
Premature Labor (Tocolysis) Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
Date:3/12/2015

Dallas, Texas (PRWEB) March 13, 2015

The report “Premature Labor (Tocolysis) – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Male Hypogonadism. Premature Labor (Tocolysis) is labor that begins more than three weeks before you are expected to deliver your baby (but after the 24th week of pregnancy). If symptoms appear before 24 weeks, this is a threatened miscarriage and not preterm labour. The symptoms of Premature Labor (Tocolysis) include regular contractions for an hour, leaking or gushing of fluid from vagina, pain that feels like menstrual cramps, with or without diarrhea and a feeling of pressure in your pelvis or lower belly. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/premature-labor-tocolysis-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. Companies discussed in this Premature Labor (Tocolysis) – Pipeline Review, H1 2015 report include Actavis plc, GlaxoSmithKline plc, Kissei Pharmaceutical Co., Ltd., and ObsEva SA.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AT-814, bedoradrine sulfate, Drug for Postpartum Depression and Premature Labor, OBE-001, OBE-002, Progesterone Second Generation, retosiban and Small Molecule to Agonize Progesterone Receptor for Preterm Birth. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310184 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor; Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221; Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound.

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2015 17
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2015 18
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2015 39
Premature Labor (Tocolysis) - Dormant Projects, H1 2015 41
Premature Labor (Tocolysis) - Discontinued Products, H1 2015 42

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Explore more reports on Women's Health Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/premature-labor-tocolysis/pipeline-review-h1-2015/prweb12579845.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks
2. Premature Births Down in U.S., But Rates Still High, Reports Say
3. PTSD in Women Linked to Premature Birth
4. Gentle caffeine boost for premature babies
5. The viability of premature babies is minimal at 22 weeks gestation
6. A new therapeutic target may prevent blindness in premature babies at risk of retinopathy
7. Scientists map risk of premature menopause after cancer treatment
8. Human milk fat improves growth in premature infants
9. Heart rate variability may predict risk of disease in premature infants
10. Women repeatedly short-changed in case of premature ejaculation
11. Prevent premature deaths from heart failure, urges the Heart Failure Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology: